Andrea K Steck1, Wiliam E Winter. 1. Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado 80045-6511, USA.
Abstract
PURPOSE OF REVIEW: The goal of this review is to provide an update on the different forms of monogenic diabetes, including maturity-onset diabetes of the young (MODY) and neonatal diabetes (permanent and transient neonatal diabetes). RECENT FINDINGS: Monogenic diabetes accounts for approximately 1-2% of diabetes cases and results from mutations that primarily reduce β-cell function. Individuals with islet autoantibody negative youth-onset forms of diabetes should be evaluated for either glucokinase-MODY or transcription factors MODY. The mild-fasting hyperglycemia found in glucokinase-MODY typically does not necessitate pharmacological treatment, whereas patients with MODY caused by transcription factor mutations can often be successfully treated with low-dose sulfonylurea. Neonatal diabetes is defined as diabetes onset within the first 6 months of life and most individuals with permanent neonatal diabetes can be treated with high-dose sulfonylurea. SUMMARY: The discovery of the genetic cause of monogenic diabetes has greatly advanced our understanding and management of these uncommon forms of diabetes.
PURPOSE OF REVIEW: The goal of this review is to provide an update on the different forms of monogenic diabetes, including maturity-onset diabetes of the young (MODY) and neonatal diabetes (permanent and transient neonatal diabetes). RECENT FINDINGS: Monogenic diabetes accounts for approximately 1-2% of diabetes cases and results from mutations that primarily reduce β-cell function. Individuals with islet autoantibody negative youth-onset forms of diabetes should be evaluated for either glucokinase-MODY or transcription factors MODY. The mild-fasting hyperglycemia found in glucokinase-MODY typically does not necessitate pharmacological treatment, whereas patients with MODY caused by transcription factor mutations can often be successfully treated with low-dose sulfonylurea. Neonatal diabetes is defined as diabetes onset within the first 6 months of life and most individuals with permanent neonatal diabetes can be treated with high-dose sulfonylurea. SUMMARY: The discovery of the genetic cause of monogenic diabetes has greatly advanced our understanding and management of these uncommon forms of diabetes.
Authors: Arthur M Lee; Cyrelle R Fermin; Stephanie L Filipp; Matthew J Gurka; Mark D DeBoer Journal: Acta Diabetol Date: 2017-01-09 Impact factor: 4.280
Authors: James T Bennett; Valeria Vasta; Min Zhang; Jaya Narayanan; Peter Gerrits; Si Houn Hahn Journal: Mol Genet Metab Date: 2014-12-20 Impact factor: 4.797
Authors: Shideh Majidi; Alexandra Fouts; Laura Pyle; Christina Chambers; Taylor Armstrong; Zhenyuan Wang; Sat Dev Batish; Georgeanna Klingensmith; Andrea K Steck Journal: Diabetes Technol Ther Date: 2018-02 Impact factor: 6.118
Authors: Matthis Synofzik; Tobias B Haack; Robert Kopajtich; Matteo Gorza; Doron Rapaport; Markus Greiner; Caroline Schönfeld; Clemens Freiberg; Stefan Schorr; Reinhard W Holl; Michael A Gonzalez; Andreas Fritsche; Petra Fallier-Becker; Richard Zimmermann; Tim M Strom; Thomas Meitinger; Stephan Züchner; Rebecca Schüle; Ludger Schöls; Holger Prokisch Journal: Am J Hum Genet Date: 2014-11-20 Impact factor: 11.025
Authors: Adrian K K Teo; Rebecca Windmueller; Bente B Johansson; Ercument Dirice; Pal R Njolstad; Erling Tjora; Helge Raeder; Rohit N Kulkarni Journal: J Biol Chem Date: 2013-01-10 Impact factor: 5.157